WO2012073254A1 - A process for the preparation of pazopanib using novel intermediate - Google Patents
A process for the preparation of pazopanib using novel intermediate Download PDFInfo
- Publication number
- WO2012073254A1 WO2012073254A1 PCT/IN2011/000781 IN2011000781W WO2012073254A1 WO 2012073254 A1 WO2012073254 A1 WO 2012073254A1 IN 2011000781 W IN2011000781 W IN 2011000781W WO 2012073254 A1 WO2012073254 A1 WO 2012073254A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pazopanib
- solvent
- methanol
- formula
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Definitions
- the present invention provides a commercially viable process for preparing pazopanib and its pharmaceutically acceptable acid addition salts thereof in high yields using novel intermediate.
- the present invention also provides a process for the purification of pazopanib hydrochloride.
- U.S. patent no. 7,105,530 disclosed pyrimidineamines and their derivatives thereof. These compounds are antineoplastic agents, and are useful in the treatment of various cancers and renal cell carcinoma.
- pazopanib hydrochloride chemically 5-[4-[N-(2,3-Dimethyl-2H-indazol-6-yl)-N-methylamino]pyrimidin-2- ylamino]-2-methylbenzenesulfonamide hydrochloride.
- Pazopanib hydrochloride is represented by the following structure:
- Pazopanib hydrochloride is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR (Vascular endothelial growth factor receptors)- 1, VEGFR-2, VEGFR-3, PDGFR (Platelet-derived growth factor receptors )-a/p, and c-kit that blocks tumor growth and inhibits angiogenesis. It has been approved for renal cell carcinoma by the U.S. Food and Drug Administration. Pazopanib hydrochloride may also be active in ovarian cancer and soft tissue sarcoma. Pazopanib hydrochloride also appears effective in the treatment of non-small cell lung carcinoma. Pazopanib hydrochloride is marketed under the brand name Votrient ® by Glaxosmithkline in the form of tablet.
- pazopanib hydrochloride can be prepared by reacting the N-(2-chloropyrimidin-4-yl)-N,2,3-trimethyl-2H-indazol-6-amine with 5- amino-2-methylbenzenesulfonamide in the presence of hydrochloric acid in isopropanol and ether.
- pazopanib hydrochloride can be prepared by reacting the N-(2-chloropyrimidin-4-yl)-N,2,3- trimethyl-2H-indazol-6-amine with 5-amino-2-methylbenzenesulfonamide in the presence of hydrochloric acid in ethanol or methanol or tetrahydrofuran or acetonitrile and dioxane.
- one object of the present invention is to provide a novel process for preparing pazopanib and pharmaceutically acceptable acid addition salts of pazopanib in high yields using novel intermediate.
- Another object of the present invention is to provide a process for the purification of pazopanib hydrochloride.
- room temperature refers to a temperature of about 25°C to about 35°C.
- the base used in step (a) may preferably be an organic base or inorganic base and more preferably the base is inorganic base selected from alkali metal hydroxides, alkali metal carbonates or alkali metal bicarbonates. Still more preferably the inorganic base is sodium bicarbonate or potassium bicarbonate.
- the solvent used in step (a) may be a solvent or mixture of solvents selected from methanol, ethanol, isopropyl alcohol, n-butanol, toluene, xylene, n-hexane, cyclohexane, methylene chloride, ethylene dichloride, chloroform, carbon tetrachloride, acetone, diethyl ketone, methyl ethyl ketone, methyl propyl ketone, methyl isobutyl ketone, methyl tert-butyl ketone, ethyl acetate, methyl acetate, isopropyl acetate, tert- butyl acetate, ethyl formate, methyl formate, tetrahydrofuran, diethyl ether, diisopropyl ether, tert-butyl methyl ether, dimethylformamide, N, N-dimethyl acetamide and
- the reaction in step (a) may preferably be carried out at ambient temperatures in the range from about -25°C to 100°C, more preferably at about 0°C to 90°C and still more preferably at about 0°C to 80°C.
- the alcoholic solvent used in step (b) may preferably be a solvent or mixture of solvents selected from methanol, ethanol, isopropyl alcohol and n-butanol, and more preferably the alcoholic solvent is ethanol or methanol.
- step (b) may preferably be carried out at an elevated temperature.
- elevated temperature refers to temperature at above 25°C. More preferably the step (b) is carried out at reflux.
- a pazopanib or a salt thereof having a purity of at least 99.9%.
- a process for the purification of pazopanib hydrochloride which comprises crystallizing pazopanib hydrochloride from a solvent system comprising alcohol solvent and water and isolating substantially pure pazopanib hydrochloride.
- substantially pure pazopanib hydrochloride refers to pazopanib hydrochloride having the purity greater than about 98% by weight, preferably greater than about 99% by weight, and more preferably greater than about 99.9% by weight.
- the alcoholic solvent used in the process may preferably be a solvent or mixture of solvents selected from methanol, ethanol, isopropanol and n-butanol, and more preferably the alcoholic solvent is methanol or isopropanol. Still more preferably the alcoholic solvent is methanol.
- Isolation of substantially pure pazopanib hydrochloride in the process can be performed by conventional methods such as cooling, removal of solvents, concentrating the reaction mass, adding an anti-solvent, extraction with a solvent and the like.
- the pH of the reaction mass was adjusted to 8.0 to 8.5 with hydrochloric acid solution (40 ml) and then added ethyl acetate (400 ml). Then the layers were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was dried with sodium sulfate and treated with carbon. The combined organic layers were washed with sodium chloride solution and dried with sodium sulfate. The organic layer was treated with carbon and filtered through hi-flow bed. The solvent was distilled off under vacuum at below 50°C to obtain a residual mass. To the residual mass was added diisopropyl ether (75 ml) and stirred for 1 hour, filtered. The solid obtained was dried to give 10 gm of N,2,3-trimethyl-2H-indazol-6-amine.
- Pazopanib hydrochloride (5 gm; HPLC Purity: 97.5%) as obtained in example 3 was dissolved in a mixture of methanol (100 ml) and water (10 ml) at room temperature and then heated to reflux. The reaction mass was maintained for 30 minutes at reflux and filtered. The filtrate obtained was cooled to room temperature and maintained for 2 hours at room temperature. The solid obtained was collected by filtration and dried to obtain 3.5 gm of pazopanib hydrochloride (HPLC Purity: 99.9%).
- Example 5 Example 5:
- Pazopanib hydrochloride 22 gm; HPLC Purity: 98%), methanol (528 ml), water (55 ml) and concentrated hydrochloric acid (0.2 ml) were added at room temperature. The contents were heated to reflux and maintained for 30 minutes, filtered. Take the filtrate and the solvent was distilled off under vacuum to obtain a residual mass. The residual mass was then cooled to room temperature and stirred for 30 minutes at room temperature. The contents were further cooled to 0 to 5°C, stirred for 1 hour and filtered. The solid obtained was dried to give 19 gm of pazopanib hydrochloride (HPLC Purity: 99.85%).
- Pazopanib hydrochloride (10 gm; HPLC Purity: 96%), methanol (250 ml), water (25 ml) and concentrated hydrochloric acid (0.1 ml) were added at room temperature. The contents were heated to reflux and maintained for 30 minutes, filtered. The filtrate obtained was then cooled to room temperature and stirred for 30 minutes at room temperature. The contents further cooled to 0 to 10°C and stirred for 1 hour. The separated solid was filtered and dried to obtain 6.6 gm of pazopanib hydrochloride (HPLC Purity: 99.8%).
- Pazopanib hydrochloride (22 gm; HPLC Purity: 97%) was dissolved in a mixture of isopropanol (132 ml) and water (20 ml) at room temperature and then heated to reflux. The reaction mass was maintained for 1 hour at reflux and then cooled to room temperature. The reaction mass was stirred for 1 hour at room temperature and filtered. The solid obtained was dried to give 18 gm of pazopanib hydrochloride (HPLC Purity: 99.8%).
Abstract
The present invention provides a commercially viable process for preparing pazopanib and its pharmaceutically acceptable acid addition salts thereof in high yields using novel intermediate. The present invention also provides a process for the purification of pazopanib hydrochloride.
Description
A PROCESS FOR THE PREPARATION OF PAZOPANIB USING NOVEL
INTERMEDIATE
Filed of the Invention
The present invention provides a commercially viable process for preparing pazopanib and its pharmaceutically acceptable acid addition salts thereof in high yields using novel intermediate. The present invention also provides a process for the purification of pazopanib hydrochloride.
Background of the Invention
U.S. patent no. 7,105,530 disclosed pyrimidineamines and their derivatives thereof. These compounds are antineoplastic agents, and are useful in the treatment of various cancers and renal cell carcinoma. Among them pazopanib hydrochloride, chemically 5-[4-[N-(2,3-Dimethyl-2H-indazol-6-yl)-N-methylamino]pyrimidin-2- ylamino]-2-methylbenzenesulfonamide hydrochloride. Pazopanib hydrochloride is represented by the following structure:
Pazopanib hydrochloride is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR (Vascular endothelial growth factor receptors)- 1, VEGFR-2, VEGFR-3, PDGFR (Platelet-derived growth factor receptors )-a/p, and c-kit that blocks tumor growth and inhibits angiogenesis. It has been approved for renal cell carcinoma by the U.S. Food and Drug Administration. Pazopanib hydrochloride may also be active in ovarian cancer and soft tissue sarcoma. Pazopanib hydrochloride also appears effective in the treatment of non-small cell lung carcinoma. Pazopanib hydrochloride is marketed under the brand name Votrient® by Glaxosmithkline in the form of tablet.
Processes for the preparation of pazopanib hydrochloride and related compounds were disclosed in U.S. patent no. 7,105,530 and U.S. patent no. 7,262,203.
According to U.S. patent no. 7,105,530, pazopanib hydrochloride can be prepared by reacting the N-(2-chloropyrimidin-4-yl)-N,2,3-trimethyl-2H-indazol-6-amine with 5-
amino-2-methylbenzenesulfonamide in the presence of hydrochloric acid in isopropanol and ether.
U.S. patent application publication no. 2006/0252943 disclosed a process for the preparation of pazopanib hydrochloride. According to this patent, pazopanib hydrochloride can be prepared by reacting the N-(2-chloropyrimidin-4-yl)-N,2,3- trimethyl-2H-indazol-6-amine with 5-amino-2-methylbenzenesulfonamide in the presence of hydrochloric acid in ethanol or methanol or tetrahydrofuran or acetonitrile and dioxane.
We have discovered a novel process for the preparation of pazopanib using novel intermediate. The process of the invention results in higher yields compared with the known process.
We have also discovered a process for the purification of pazopanib hydrochloride.
Thus, one object of the present invention is to provide a novel process for preparing pazopanib and pharmaceutically acceptable acid addition salts of pazopanib in high yields using novel intermediate.
Another object of the present invention is to provide a process for the purification of pazopanib hydrochloride. Detailed Description of the Invention
As used herein the term "room temperature" refers to a temperature of about 25°C to about 35°C.
According to one aspect of the present invention, there is provided a novel process for the preparation of pazopanib of formula I:
which comprises:
a) reacting 5-amino-2-methylbenzenesulfonamide of formula II:
Preferably the solvent used in step (a) may be a solvent or mixture of solvents selected from methanol, ethanol, isopropyl alcohol, n-butanol, toluene, xylene, n-hexane, cyclohexane, methylene chloride, ethylene dichloride, chloroform, carbon tetrachloride, acetone, diethyl ketone, methyl ethyl ketone, methyl propyl ketone, methyl isobutyl ketone, methyl tert-butyl ketone, ethyl acetate, methyl acetate, isopropyl acetate, tert- butyl acetate, ethyl formate, methyl formate, tetrahydrofuran, diethyl ether, diisopropyl ether, tert-butyl methyl ether, dimethylformamide, N, N-dimethyl acetamide and dimethyl sulfoxide. Most preferably the solvents are methanol, ethanol, tetrahydrofuran and diisopropyl ether, and still more preferably the solvents are ethanol and tetrahydrofuran.
The reaction in step (a) may preferably be carried out at ambient temperatures in the range from about -25°C to 100°C, more preferably at about 0°C to 90°C and still more preferably at about 0°C to 80°C.
The alcoholic solvent used in step (b) may preferably be a solvent or mixture of solvents selected from methanol, ethanol, isopropyl alcohol and n-butanol, and more preferably the alcoholic solvent is ethanol or methanol.
The reaction in step (b) may preferably be carried out at an elevated temperature. The term "elevated temperature" refers to temperature at above 25°C. More preferably the step (b) is carried out at reflux.
According to another aspect of the present invention, there is provided a novel compound of formula IV:
According to another aspect of the present invention, there is provided a process for the purification of pazopanib hydrochloride, which comprises crystallizing pazopanib hydrochloride from a solvent system comprising alcohol solvent and water and isolating substantially pure pazopanib hydrochloride.
The term "substantially pure pazopanib hydrochloride" refers to pazopanib hydrochloride having the purity greater than about 98% by weight, preferably greater than about 99% by weight, and more preferably greater than about 99.9% by weight.
The alcoholic solvent used in the process may preferably be a solvent or mixture of solvents selected from methanol, ethanol, isopropanol and n-butanol, and more preferably the alcoholic solvent is methanol or isopropanol. Still more preferably the alcoholic solvent is methanol.
Isolation of substantially pure pazopanib hydrochloride in the process can be performed by conventional methods such as cooling, removal of solvents, concentrating the reaction mass, adding an anti-solvent, extraction with a solvent and the like.
The purity of pazopanib hydrochloride is measured by High performance liquid chromatography (HPLC).
The invention will now be further described by the following example, which is illustrative rather than limiting.
Examples
Example 1:
Preparation of 5-(4-chloropyrimidin-2ylamino)-2-methyIbenzenesulfonamide
To a mixture of 5-amino-2-methylbenzenesulfonamide (20 gm) in ethanol (208 ml) and tetrahydrofuran (52 ml) was added 2,4-dichloropryrimidine (44 gm) and sodium bicarbonate (36 gm) at room temperature. The contents were heated to 70 to 75°C and maintained for 13 hours. The reaction mass was then cooled to 10°C and maintained for 2 hours. The reaction mass was filtered and the solvent was distilled off under vacuum at below 50 to 55°C to obtain a residual mass. To the residual mass was added ethyl acetate (100 ml) and stirred for 1 hour, filtered. The solid obtained was dried to give 15.5 gm of 5-(4-chloropyrimidin-2ylamino)-2-methylbenzenesulfonamide.
Example 2:
Preparation of N,2,3-trimethyI-2H-indazol-6-amine
Sodium methoxide (19 gm) was dissolved in methanol (610 ml) and then added 2,3-dimethyl-2H-indazol-6-amine (13 gm). The reaction mixture was stirred for 15 minutes and then added paraformaldehyde (3.9 gm). The contents were heated to 60°C and stirred for 10 hours. The reaction mass was then cooled to room temperature and maintained for 4 hours 30 minutes. Sodium borohydride (2.8 gm) was added to the reaction mass slowly at room temperature and then heated to reflux. The reaction mass was maintained for 2 hours at reflux and then cooled to room temperature. The reaction mass was stirred for 14 hours at room temperature and then added sodium hydroxide solution (1M, 100 ml). The pH of the reaction mass was adjusted to 8.0 to 8.5 with hydrochloric acid solution (40 ml) and then added ethyl acetate (400 ml). Then the layers were separated and the aqueous layer was extracted with ethyl acetate. The organic layer was dried with sodium sulfate and treated with carbon. The combined organic layers were washed with sodium chloride solution and dried with sodium sulfate. The organic layer was treated with carbon and filtered through hi-flow bed. The solvent was distilled off under vacuum at below 50°C to obtain a residual mass. To the residual mass was added diisopropyl ether (75 ml) and stirred for 1 hour, filtered. The solid obtained was dried to give 10 gm of N,2,3-trimethyl-2H-indazol-6-amine.
Example 3:
Preparation of pazopanib hydrochloride
5-(4-Chloropyrimidin-2ylamino)-2-methylbenzenesulfonamide (17 gm) as obtained in example 1, N,2,3-trimethyl-2H-indazol-6-amine (10 gm) as obtained in example 2 and ethanol (166 ml) were added at room temperature and then heated to reflux. The reaction mass was maintained for 3 hours at reflux and then added concentrated hydrochloric acid (1 ml). The reaction mass was maintained for 10 hours at reflux and then cooled to room temperature. The separated solid was filtered and dried to obtain 17 gm of pazopanib hydrochloride (HPLC Purity: 97.5%).
Example 4:
Purification of pazopanib hydrochloride
Pazopanib hydrochloride (5 gm; HPLC Purity: 97.5%) as obtained in example 3 was dissolved in a mixture of methanol (100 ml) and water (10 ml) at room temperature and then heated to reflux. The reaction mass was maintained for 30 minutes at reflux and filtered. The filtrate obtained was cooled to room temperature and maintained for 2 hours at room temperature. The solid obtained was collected by filtration and dried to obtain 3.5 gm of pazopanib hydrochloride (HPLC Purity: 99.9%). Example 5:
Purification of pazopanib hydrochloride
Pazopanib hydrochloride (22 gm; HPLC Purity: 98%), methanol (528 ml), water (55 ml) and concentrated hydrochloric acid (0.2 ml) were added at room temperature. The contents were heated to reflux and maintained for 30 minutes, filtered. Take the filtrate and the solvent was distilled off under vacuum to obtain a residual mass. The residual mass was then cooled to room temperature and stirred for 30 minutes at room temperature. The contents were further cooled to 0 to 5°C, stirred for 1 hour and filtered. The solid obtained was dried to give 19 gm of pazopanib hydrochloride (HPLC Purity: 99.85%).
Example 6:
Purification of pazopanib hydrochloride
Pazopanib hydrochloride (10 gm; HPLC Purity: 96%), methanol (250 ml), water (25 ml) and concentrated hydrochloric acid (0.1 ml) were added at room temperature. The contents were heated to reflux and maintained for 30 minutes, filtered. The filtrate obtained was then cooled to room temperature and stirred for 30 minutes at room temperature. The contents further cooled to 0 to 10°C and stirred for 1 hour. The separated solid was filtered and dried to obtain 6.6 gm of pazopanib hydrochloride (HPLC Purity: 99.8%).
Example 7:
Purification of pazopanib hydrochloride
Pazopanib hydrochloride (22 gm; HPLC Purity: 97%) was dissolved in a mixture of isopropanol (132 ml) and water (20 ml) at room temperature and then heated to reflux. The reaction mass was maintained for 1 hour at reflux and then cooled to room temperature. The reaction mass was stirred for 1 hour at room temperature and filtered. The solid obtained was dried to give 18 gm of pazopanib hydrochloride (HPLC Purity: 99.8%).
Claims
1. A novel p :
or a pharmaceutically acceptable salt thereof:
which comprises:
a) reacting 5-amino-2-methylbenzenesulfonamide of formula II:
with a 2,4-dichloropryrimidine of formula III: 
in presence of a base and a solvent to give 5-(4-chloropyrimidin-2ylamino)-2- methylbenzenesulfonamide of formula IV; and
b) condensing the 5-(4-chloropyrimidin-2ylamino)-2-methylbenzenesulfonamide of formula IV with the N,2,3-trimethyl-2H-indazol-6-amine of formula V:
■V
2. The process as claimed in claim 1, wherein the base used in step (a) is an organic base or inorganic base.
3. The process as claimed in claim 2, wherein the base is inorganic base selected from alkali metal hydroxides, alkali metal carbonates or alkali metal bicarbonates.
4. The process as claimed in claim 3, wherein the inorganic base is sodium bicarbonate or potassium bicarbonate.
5. The process as claimed in claim 1, wherein the solvent is a solvent or mixture of solvents selected from methanol, ethanol, isopropyl alcohol, n-butanol, toluene, xylene, n-hexane, cyclohexane, methylene chloride, ethylene dichloride, chloroform, carbon tetrachloride, acetone, diethyl ketone, methyl ethyl ketone, methyl propyl ketone, methyl isobutyl ketone, methyl tert-butyl ketone, ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl acetate, ethyl formate, methyl formate, tetrahydrofuran, diethyl ether, diisopropyl ether, tert-butyl methyl ether, dimethylformamide, N, N-dimethyl acetamide and dimethyl sulfoxide.
6. The process as claimed in claim 5, wherein the solvents are methanol, ethanol, tetrahydrofuran and diisopropyl ether.
7. The process as claimed in claim 1, wherein the alcoholic solvent used in step (b) is a solvent or mixture of solvents selected from methanol, ethanol, isopropyl alcohol and n-butanol.
8. The process as claimed in claim 7, wherein the alcoholic solvent is ethanol or methanol.
9. The process as claimed in claim 1, wherein the reaction in step (b) is carried out at an elevated temperature.
10. The process as claimed in claim 9, wherein the reaction in step (b) is carried out at above 25°C.
11. A novel compound of formula IV: 
12. A pazopanib or a salt thereof having a purity of at least 99.9%.
13. A process for the purification of pazopanib hydrochloride, which comprises crystallizing pazopanib hydrochloride from a solvent system comprising alcohol solvent and water and isolating substantially pure pazopanib hydrochloride.
14. The process as claimed in claim 13, wherein the alcoholic solvent used in the process is a solvent or mixture of solvents selected from methanol, ethanol, isopropanol and n-butanol.
15. The process as claimed in claim 14, wherein the alcoholic solvent is methanol or isopropanol.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/989,541 US9150547B2 (en) | 2010-11-29 | 2011-11-11 | Process for the preparation of pazopanib using novel intermediate |
| EP11845075.8A EP2646431B1 (en) | 2010-11-29 | 2011-11-11 | A process for the preparation of pazopanib using novel intermediate |
| CA2819118A CA2819118A1 (en) | 2010-11-29 | 2011-11-11 | A process for the preparation of pazopanib using novel intermediate |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3590/CHE/2010 | 2010-11-29 | ||
| IN3590CH2010 | 2010-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2012073254A1 true WO2012073254A1 (en) | 2012-06-07 |
Family
ID=46171268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2011/000781 WO2012073254A1 (en) | 2010-11-29 | 2011-11-11 | A process for the preparation of pazopanib using novel intermediate |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9150547B2 (en) |
| EP (1) | EP2646431B1 (en) |
| CA (1) | CA2819118A1 (en) |
| WO (1) | WO2012073254A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103232443A (en) * | 2013-02-01 | 2013-08-07 | 天津药物研究院 | Indazole derivative crystal and its preparation method and use |
| WO2014085373A1 (en) * | 2012-11-27 | 2014-06-05 | Glaxosmithkline Llc | Combination |
| WO2015031604A1 (en) | 2013-08-28 | 2015-03-05 | Crown Bioscience, Inc. | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same |
| CN104557881A (en) * | 2014-12-30 | 2015-04-29 | 山东博迈康药物研究有限公司 | Preparation method of pazopanib hydrochloride crystal form |
| CN110028495A (en) * | 2019-05-24 | 2019-07-19 | 济南爱思医药科技有限公司 | The environment-friendly preparation method thereof of pazopanib hydrochloride |
| US10730859B2 (en) | 2013-11-05 | 2020-08-04 | Laurus Labs Limited | Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252943A1 (en) * | 2002-06-17 | 2006-11-09 | Amogh Boloor | Chemical process |
| US20080269170A1 (en) * | 2005-07-11 | 2008-10-30 | Sanofi-Aventis | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122010000038I1 (en) | 2000-12-21 | 2011-01-27 | Glaxosmithkline Llc | PYRIMIDINAMINES AS ANGIOGENESIS MODULATORS |
| US8084457B2 (en) * | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
-
2011
- 2011-11-11 EP EP11845075.8A patent/EP2646431B1/en not_active Not-in-force
- 2011-11-11 WO PCT/IN2011/000781 patent/WO2012073254A1/en active Application Filing
- 2011-11-11 CA CA2819118A patent/CA2819118A1/en not_active Abandoned
- 2011-11-11 US US13/989,541 patent/US9150547B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252943A1 (en) * | 2002-06-17 | 2006-11-09 | Amogh Boloor | Chemical process |
| US20080269170A1 (en) * | 2005-07-11 | 2008-10-30 | Sanofi-Aventis | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors |
Non-Patent Citations (2)
| Title |
|---|
| LUO G. ET AL.: "Microwave-assisted synthesis of aminopyrimidines", TETRAHEDRON LETTERS, vol. 43, no. 33, 2002, pages 5739 - 5742, XP004372432 * |
| See also references of EP2646431A4 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014085373A1 (en) * | 2012-11-27 | 2014-06-05 | Glaxosmithkline Llc | Combination |
| CN103232443A (en) * | 2013-02-01 | 2013-08-07 | 天津药物研究院 | Indazole derivative crystal and its preparation method and use |
| WO2015031604A1 (en) | 2013-08-28 | 2015-03-05 | Crown Bioscience, Inc. | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same |
| US10730859B2 (en) | 2013-11-05 | 2020-08-04 | Laurus Labs Limited | Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof |
| US11299477B2 (en) | 2013-11-05 | 2022-04-12 | Laurus Labs Limited | Process for the preparation of Pazopanib or a pharmaceutically acceptable salt thereof |
| US11427570B2 (en) | 2013-11-05 | 2022-08-30 | Laurus Labs Limited | Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof |
| CN104557881A (en) * | 2014-12-30 | 2015-04-29 | 山东博迈康药物研究有限公司 | Preparation method of pazopanib hydrochloride crystal form |
| CN104557881B (en) * | 2014-12-30 | 2017-08-11 | 山东博迈康药物研究有限公司 | A kind of preparation method of pazopanib hydrochloride crystal formation |
| CN110028495A (en) * | 2019-05-24 | 2019-07-19 | 济南爱思医药科技有限公司 | The environment-friendly preparation method thereof of pazopanib hydrochloride |
Also Published As
| Publication number | Publication date |
|---|---|
| US9150547B2 (en) | 2015-10-06 |
| US20130245262A1 (en) | 2013-09-19 |
| EP2646431A4 (en) | 2014-04-30 |
| EP2646431A1 (en) | 2013-10-09 |
| CA2819118A1 (en) | 2012-06-07 |
| EP2646431B1 (en) | 2016-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2646431B1 (en) | A process for the preparation of pazopanib using novel intermediate | |
| JP5535082B2 (en) | Method for synthesizing bosentan, polymorphic forms thereof and salts thereof | |
| CA2848631C (en) | Rilpivirine hydrochloride | |
| AU2002360386A1 (en) | Amorphous and crystalline forms of losartan potassium and process for their preparation | |
| WO2012082972A1 (en) | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine | |
| EP1476442A2 (en) | Lansoprazole polymorphs and processes for preparation thereof | |
| CZ2005679A3 (en) | Method of removing triphenylmethane protecting group in anti-hypertension medicament precursors | |
| EP2294056A1 (en) | Bosentan salts | |
| WO2011018101A1 (en) | Lenalidomide salts | |
| US9624207B2 (en) | Polymorphs of azilsartan medoxomil | |
| CA2912902A1 (en) | Polymorphic forms of nilotinib hydrochloride | |
| WO2012001695A1 (en) | A process for etra virine intermediate and polymorphs of etravirine | |
| JP2007524643A (en) | Preparation of tegaserod and tegaserod maleate | |
| WO2017191539A1 (en) | Process for the preparation dl-proline co-crystal of dapagliflozin | |
| CN104829590B (en) | Method for purifying trelagliptin | |
| WO2008111016A1 (en) | Process for the preparation of pure prulifloxacin | |
| WO2015049698A2 (en) | Process for regorafenib | |
| WO2013150544A2 (en) | Ivabradine hydrochloride solid dispersion | |
| WO2010146428A1 (en) | An improved process for the preparation of rabeprazole | |
| WO2015092624A1 (en) | Nilotinib mono-oxalate and its crystalline form | |
| WO2013162390A1 (en) | Process for preparation of high purity n- [2- (diethylamine) ethyl] - 5 - formyl - 2, 4 - dimethyl - 1h - pyrrole - 3 - carboxyamide | |
| WO2011020189A1 (en) | Forms of dexlansoprazole and processes for the preparation thereof | |
| WO2014136126A2 (en) | A process for preparing erlotinib hydrochloride form a | |
| US20150336900A1 (en) | Process for the Synthesis of Etravirine and Its Intermediates | |
| US20150291574A1 (en) | Novel polymorphs of azilsartan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11845075 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011845075 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 13989541 Country of ref document: US |
|
| ENP | Entry into the national phase |
Ref document number: 2819118 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |